Format

Send to

Choose Destination
Endocr Relat Cancer. 2013 May 20;20(3):R83-99. doi: 10.1530/ERC-12-0394. Print 2013 Jun.

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

Author information

1
Division of Medical Oncology, Duke Cancer Institute, Duke University, DUMC Box 102002, Durham, North Carolina 27710, USA.

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer.

KEYWORDS:

Akt; PI3K inhibitors; PI3K pathway; androgen receptor signaling; castration-resistant prostate cancer (CRPC); combination therapy; mTOR

PMID:
23456430
DOI:
10.1530/ERC-12-0394
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center